FDA Clears Generic HIV Shot for Global Access at $40 Annual Cost

Key points

• The FDA approved a generic version of lenacapavir, the only twice-yearly HIV prevention shot, under a tentative designation while the brand-name patent remains active.
• The generic is expected to cost $40 per person annually in 120 low- and middle-income countries, matching the price of current daily preventive pills.
• The brand-name version, Yeztugo by Gilead Sciences, costs $28,218 annually in the U.S. and cannot be sold domestically as a generic due to patent protections.
• Gilead established royalty-free licensing agreements with six generic manufacturers last year to enable production in sub-Saharan Africa, Asia, and Latin America.
• The generic was developed by India-based Dr. Reddy’s Laboratories under an agreement brokered by Unitaid, the Clinton Health Access Initiative, and Wits RHI.
• Advocates estimate that 20 million people worldwide need pre-exposure prophylaxis (PrEP), and scaling access could help end the HIV epidemic.

Background

This development follows the approval of the brand-name lenacapavir (Yeztugo) by Gilead Sciences last year, which faced supply shortages in low-income regions. The generic approval builds on earlier efforts to reduce the cost of HIV prevention, aligning with global health goals to expand access to PrEP. Recent discussions around PrEP stigma and accessibility in conservative environments highlight the ongoing challenges in normalizing HIV prevention, particularly for diverse populations. The FDA’s tentative approval leverages longstanding practices to ensure quality for HIV-related drugs provided to other countries by the U.S. government, potentially speeding up regulatory approvals in other nations.

Why it matters

The approval of a generic lenacapavir at a significantly lower cost could dramatically expand access to HIV prevention in low- and middle-income countries, where demand currently exceeds supply. By matching the price of daily preventive pills and offering a more convenient twice-yearly injection, the generic could improve adherence and reduce new infections. Scaling access to the estimated 20 million people who need PrEP could help curb the HIV epidemic, potentially reducing the 570,000 annual HIV-related deaths reported by the World Health Organization. This milestone underscores the importance of affordable, high-quality medications in global health efforts.

What to watch

Generic lenacapavir is expected to become available in some locations within weeks, with broader rollout anticipated in 2027. Other generic manufacturers are yet to receive FDA approval. Advocates emphasize the need for funding to purchase the drug for all who need it and to navigate the logistical challenges of distribution. Gilead has stated that its royalty-free licensing agreements aim to enable the fastest and most sustainable path to expanding access. Continued monitoring of side effects and adherence will be crucial as the drug is deployed in diverse populations.